Four prominent Wall Street broker-dealers downgraded Phreesia on Monday in reaction to a substantial trimming of the company’s fiscal 2027 revenue guidance, a move that sent the stock falling more than 26% in premarket trading on Tuesday.
The group of analysts from Baird, Truist Securities, JPMorgan and Citi each moved their ratings from Buy to the equivalent of Neutral and slashed price targets to a range between $10 and $16.
The catalyst for the collective reassessment was Phreesia’s decision to lower FY27 revenue guidance by about $35 million to $39 million, bringing the range to $510 million to $520 million. That sits well under the consensus figure of roughly $552 million.
Company management attributed the revision to reduced spending commitments from select pharmaceutical manufacturers, with named areas of weakness in vaccines, GLP-1 products and public health spending. The updated outlook implies a slowdown to low-single-digit organic revenue growth, compared with the 8-10% growth pace Phreesia had been projecting earlier.
Despite the revenue downgrade, Phreesia kept its adjusted EBITDA forecast unchanged at $125 million to $135 million, pointing to operating leverage and anticipated efficiency gains driven by AI initiatives as offsets to weaker top-line trends.
Operational results for the fourth quarter offered mixed signals. Phreesia reported revenue of $127 million, up 16% year-over-year, and adjusted EBITDA of $29 million, both slightly ahead of street estimates. The quarter also represented the company’s first full year of positive GAAP net income and a record quarterly free cash flow tally of $28.5 million. Nevertheless, those financial positives were eclipsed in market reaction by the company’s forward-looking downgrade.
Analysts expressed concern about the scale and implications of the guidance change. Truist Securities analyst Jailendra Singh described the magnitude as surprising given management had earlier called its preliminary outlook a "conservative" baseline. Singh wrote that the narrative had shifted from a "Show Me" story to one of "No Growth Visibility," and said his firm was downgrading to Hold.
JPMorgan’s Alexei Gogolev flagged execution risk associated with the company’s strategy to make up for lower revenue through cost reductions and AI-related efficiency. He acknowledged the company’s deliberate moderation of subscription pricing to bolster retention and adoption and to drive downstream monetization in payments solutions, but cautioned that the timing of emphasizing the less-certain Network Solutions revenue stream "appears unfortunate."
Citi’s Daniel Grosslight suggested the shares were likely to be range-bound in the near term absent clearer signs around pharmaceutical direct-to-consumer advertising spend, the realization of AI-driven operating leverage, and evidence of traction in early-stage businesses such as AccessOne and HCP advertising.
Baird analyst Joe Vruwink noted that the revenue cut was "more than we expected," and said it likely prolongs the overhang on the stock amid broader debates about AI and SaaS sector dynamics.
In addition to the analyst reaction and share-price weakness, promotional content included in market commentary referenced ProPicks AI, an AI-driven stock selection product that evaluates PHR among other companies. That content highlighted the product’s use of financial metrics and past performance comparisons, but does not alter the core financial facts and guidance figures disclosed by Phreesia and summarized above.